Morningstar highlights undervalued international stocks, including AstraZeneca and…
1 report, 1 independent
Updated Sep 22
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Morningstar published a segment discussing undervalued international stocks available to US investors via ADRs. The firm highlighted AstraZeneca as an undervalued pick, noting its strong pipeline, particularly in cancer drugs, and its pricing power. The report also recommended companies based in the Netherlands, such as ASML.
From morningstar.com
Why it matters
The discussion centered on the potential value of companies like AstraZeneca, which Morningstar valued at $184. The report detailed how these companies operate, including AstraZeneca's successful portfolio in hard-to-treat cancers.
From morningstar.com
Who's involved
- AstraZenecaBritish-Swedish pharmaceutical company praised for its strong pipeline and pricing power.
- NetherlandsCountry where companies like ASML are based and discussed in the report.
Keep exploring
The entities involved
-
Netherlands
one of the four autonomous countries of the Kingdom of the Netherlands; with territories in the Caribbean
-
AstraZeneca
British-Swedish pharmaceutical company
Related events
- Biofrontera and AstraZeneca are being compared as healthcare companies for investment.
- FactSet surveyed analysts regarding the Netherlands-based company ASML.
- AstraZeneca and Teva Pharmaceutical Industries Limited are being compared as large-cap healthcare companies regarding their revenue and earnings.
- AstraZeneca plans a $2B facility in Tuas, Singapore, while President Shanmugaratnam conducts a state visit to Sweden.